Idorsia's Tryvio crosses FDA finish line, offering new mechanism to treat hypertension

After Johnson & Johnson last year changed its mind on its 2017 purchase of aprocitentan, the medicine's original maker has ushered the drug across the FDA finish line.

The once-daily drug, branded as Tryvio, is now approved to treat hypertension, or high blood pressure, when combined with other anti-hypertensive drugs, Idorsia said Wednesday.